91㽶Ƶ to Present on Integrated UpTempo℠ Gene Therapy Development Platform at Upcoming ASGCT Annual Meeting
SOMERSET, N.J. – May 16, 2023 — 91㽶Ƶ, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that George Buchman, Ph.D., Vice President, Pre-Clinical and Process Development, will present at the upcoming 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held at the Los Angeles Convention Center on May 16-20, 2023.
Dr. Buchman’s presentation, on Friday, May 19, at 4:30 p.m. PDT, is entitled “One-stop Integrated Viral Vector Platform for Speed to Clinic,” and will focus on a consolidated and standardized platform to help fast-track AAV vectors to the clinic with a scalable CGMP-ready process. The complete UpTempo℠ AAV platform, which was re-launched in its expanded form in March 2023, provides increased consistency and efficiency, reducing the time to manufacture clinical-quality drug product to just nine months, while delivering a process that will readily advance to late-stage CGMP manufacture.
Dr. Buchman works in 91㽶Ƶ’s Cell & Gene Therapy business, which provides research services and process development and enables the translation of programs into clinical trials and commercial CGMP manufacturing. He has worked more than 30 years in the biotech industry, including at Life Technologies (now Thermo Fisher Scientific), Celera Genomics, and GeneLogic. Dr. Buchman obtained his bachelor’s degree in biochemistry from Albright College, Reading, Pennsylvania, and his doctorate in biochemistry from the University of Maryland.
91㽶Ƶ will also be exhibiting at the conference, in booth 229. To find out more information about this event, visit /events/asgct-annual-meeting-2023/ and to find out more about 91㽶Ƶ’s UpTempo AAV platform, visit 91㽶Ƶ.com/UpTempo.
NOTES FOR EDITORS
ABOUT CATALENT CELL AND GENE THERAPY
91㽶Ƶ Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vaccines, 91㽶Ƶ is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, and oncolytic viruses. As an experienced and innovative partner, it has a global network of dedicated, development, clinical, and commercial manufacturing facilities, including an EMA- and FDA-licensed viral vector facility, and fill/finish capabilities located in the U.S. and Europe. With integrated solutions for plasmid DNA, viral vectors, and autologous and allogeneic cell therapies through clinical trial packaging and logistics, 91㽶Ƶ can provide full supply chain control, helping innovators get their advanced therapies to patients, faster.
ABOUT CATALENT
91㽶Ƶ is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, 91㽶Ƶ is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.
91㽶Ƶ helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. 91㽶Ƶ’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.
Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit .